Analytical Data
-
基因名
FDFT1
- Application
-
别名
FDFT1;Squalene synthase
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P37268
-
表达区间
1-283aa
-
氨基酸序列
MGSSHHHHHH SSGLVPRGSH MGSMEFVKCL GHPEEFYNLV RFRIGGKRKV MPKMDQDSLS SSLKTCYKYL NQTSRSFAAV IQALDGEMRN AVCIFYLVLR ALDTLEDDMT ISVEKKVPLL HNFHSFLYQP DWRFMESKEK DRQVLEDFPT ISLEFRNLAE KYQTVIADIC RRMGIGMAEF LDKHVTSEQE WDKYCHYVAG LVGIGLSRLF SASEFEDPLV GEDTERANSM GLFLQKTNII RDYLEDQQGG REFWPQEVWS RYVKKLGDFA KPENIDLAVQ CLNELITNAL HHIPDVITYL SRLRNQ
-
分子量
35 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FDFT1, or Farnesyl Diphosphate Synthase 1, is an enzyme that plays a crucial role in the mevalonate pathway, which is essential for the biosynthesis of sterols and isoprenoids in eukaryotic cells. This pathway is vital for producing cholesterol, a fundamental component of cell membranes, and precursors for various signaling molecules. Dysregulation of FDFT1 has been linked to several diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions, highlighting its potential as a therapeutic target. Research on the recombinant protein FDFT1 aims to better understand its enzymatic mechanisms, substrate specificity, and regulation, facilitating the development of inhibitors that could serve as clinical treatments. Recent advancements in structural biology and protein engineering techniques have enhanced our ability to produce and characterize FDFT1, allowing for detailed studies of its active site and interaction with regulatory molecules. The investigation of FDFT1 not only provides insights into fundamental metabolic processes but also offers a pathway for developing novel therapeutics aimed at modulating lipid metabolism and related diseases.
